Peel’s pipeline programs currently target high unmet clinical need areas in which patients face limited or no viable treatment options in oncology and inflammatory diseases. We are selective and engineer programs for radical impact, ensuring each drug has the potential to have a staggering impact for patients across efficacy and safety. 


A new cancer medicine engineered to avoid chemotherapy resistance. It originates from an ancient tree a plant stem used for more than 2,000 years in Eastern Traditional Chinese medicine.  

PEEL-224 is a nanocarrier linked to 4 small molecules developed for the treatment of cancer. The active molecule of PEEL-224 derives from camptothecin, a naturally occurring compound found in the Chinese Happy Tree thought to have evolved as a plant defense mechanism. Camptothecin and its derivatives inhibit topoisomerase 1 DNA repair, effectively killing dividing cells. By engineering the natural molecule and conjugating it with a synthetic polymer, PEEL-224 is designed to improve efficacy while limiting toxicity.  


The robust preclinical data gathered to date has been extremely promising, showing that PEEL-224 has a sustained complete response in various solid tumors for more than six months. The molecular structure of Peel’s drug prevents its efflux from cancer cells through the ABCG2 multidrug transporter pump, meaning tumors are less likely to become resistant to PEEL-224 treatment and this drug can overcome irinotecan resistance.  


The PEEL-224 manufacturing process is optimized, scaled for the clinic and ready to treat patients. Our first clinical trial for PEEL-224 (NCT05329103) has been initiated.


EP53 Lipid Nanoparticles

A potent elephant tumor suppressor gene for the treatment of cancer, to be delivered by lipid nanoparticles. We are developing our EP53 nanoparticles as a replacement therapy for TP53, the most commonly mutated gene in human cancers. 
NVT Luc LNPs.jpg

TP53 is a tumor suppressor gene often referred to as the “Guardian of the Genome.” TP53 plays an essential role in destroying cancerous tissues, but is often turned off in the majority of human cancers. While humans have two copies of this gene, elephants have 40 copies of EP53 (elephant p53) – a scientific discovery published in the Journal of the American Medical Association (JAMA) by Peel co-founder Dr. Joshua Schiffman and his collaborators, some of whom are currently employed at Peel.   


For effective EP53 drug delivery, we are harnessing a nanotechnology that enables potent, enhanced delivery of the payload. This type of drug delivery modality has been pioneered by Peel co-founder Dr. Avi Schroeder, an internationally recognized expert in nanotechnology. 

Red circles = Peel's proprietary nanoparticles delivered to Human cells in vitro

We are currently evaluating our EP53 nanoparticles in rigorous preclinical studies, with promising results.

Neutrophil Targeting Peptide (NTP)

An anti-inflammatory peptide originally isolated from newborns to block inflammation and immunothrombosis.  

We have developed first-in-class neutrophil-targeting peptides (NTPs) for the treatment of inflammatory diseases and immune-triggered thrombosis. Our NTPs are modified from natural neutrophil extracellular trap (NET) inhibitors: peptides of natural origin with anti-inflammatory, evolutionary mechanisms only present during the first few days of life and help newborns avoid an overwhelming immune response as they adapt to their new, microbial-rich environment. NETs are sticky webs of DNA released from neutrophils and contribute to acute and chronic inflammation and immunothrombosis.  

Our NTPs are natural NET inhibitors that block the overactive immune response of neutrophils, which can lead to organ and vascular damage in many human diseases. There is immense potential to assess NTPs for the treatment of sepsis, ARDS, stroke, thrombosis, asthma, diabetes, kidney failure, myocardial infarction and inflammation, and even COVID-19. NTPs demonstrate strong and reproducible efficacy in multiple preclinical models of inflammatory diseases. For example, NTPs increase survival in mice with sepsis from 0% to more than 70% overall survival, reduce lung inflammation due to bacterial toxins, and nearly eliminate the paralysis seen in stroke from reperfusion injury.  

We are rapidly advancing our nonclinical studies and manufacturing for our NTP program.

The Peel team is uniquely positioned to succeed, with exclusive licensing and patents surrounding each asset.